TY - JOUR
T1 - Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models
AU - Apisarnthanarax, Smith
AU - Alauddin, Mian M.
AU - Mourtada, Firas
AU - Ariga, Hisanori
AU - Raju, Uma
AU - Mawlawi, Osama
AU - Han, Dongmei
AU - Bornmann, William G.
AU - Ajani, Jaffer A.
AU - Milas, Luka
AU - Gelovani, Juri G.
AU - Chao, K. S.Clifford
PY - 2006/8/1
Y1 - 2006/8/1
N2 - Purpose: Early identification of esophageal cancer patients who are responding or resistant to combined chemoradiotherapy may lead to individualized therapeutic approaches and improved clinical outcomes. We assessed the ability of 3′-deoxy-3′-18F-fluorothymidine positron emission tomography (FLT-PET) to detect early changes in tumor proliferation after chemoradiotherapy in experimental models of esophageal carcinoma. Experimental Design: The in vitro and ex vivo tumor uptake of [3H]FLT in SEG-1 human esophageal adenocarcinoma cells were studied at various early time points after docetaxel plus irradiation and validated with conventional assessments of cellular proliferation [thymidine (Thd) and Ki-67] and [18F]FLT micro-PET imaging. Imaging-histologic correlation was determined by comparing spatial Ki-67 and [18F] FLT distribution in autoradiographs. Comparison with fluorodeoxyglucose (FDG) was done in all experiments. Results: In vitro [3H] FLTand [3H]THd uptake rapidly decreased in SEG-1 cells 24 hours after docetaxel with a maximal reduction of over 5-fold (P - 0.005). The [3H]FLT tumor-to-muscle uptake ratio in xenografts declined by 75% compared with baseline (P < 0.005) by 2 days after chemoradiotherapy, despite the lack of change in tumor size. In contrast, the decline of [3H] FDG uptake was gradual and less pronounced. Tumor uptake of [3H] FLT was more closely correlated with Ki-67 expression (r = 0.89, P < 0.001) than was [3H]FDG (r = 0.39, P = 0.08). Micro-PET images depicted similar trends in reduction of [18F]FLT and [ 18F]FDG tumor uptake. Autoradiographs displayed spatial correlations between [18F] FLT uptake and histologic Ki-67 distribution in preliminary studies. Conclusions: FLT-PET is suitable and more specific than FDG-PET for depicting early reductions in tumor proliferation that precede tumor size changes after chemoradiotherapy.
AB - Purpose: Early identification of esophageal cancer patients who are responding or resistant to combined chemoradiotherapy may lead to individualized therapeutic approaches and improved clinical outcomes. We assessed the ability of 3′-deoxy-3′-18F-fluorothymidine positron emission tomography (FLT-PET) to detect early changes in tumor proliferation after chemoradiotherapy in experimental models of esophageal carcinoma. Experimental Design: The in vitro and ex vivo tumor uptake of [3H]FLT in SEG-1 human esophageal adenocarcinoma cells were studied at various early time points after docetaxel plus irradiation and validated with conventional assessments of cellular proliferation [thymidine (Thd) and Ki-67] and [18F]FLT micro-PET imaging. Imaging-histologic correlation was determined by comparing spatial Ki-67 and [18F] FLT distribution in autoradiographs. Comparison with fluorodeoxyglucose (FDG) was done in all experiments. Results: In vitro [3H] FLTand [3H]THd uptake rapidly decreased in SEG-1 cells 24 hours after docetaxel with a maximal reduction of over 5-fold (P - 0.005). The [3H]FLT tumor-to-muscle uptake ratio in xenografts declined by 75% compared with baseline (P < 0.005) by 2 days after chemoradiotherapy, despite the lack of change in tumor size. In contrast, the decline of [3H] FDG uptake was gradual and less pronounced. Tumor uptake of [3H] FLT was more closely correlated with Ki-67 expression (r = 0.89, P < 0.001) than was [3H]FDG (r = 0.39, P = 0.08). Micro-PET images depicted similar trends in reduction of [18F]FLT and [ 18F]FDG tumor uptake. Autoradiographs displayed spatial correlations between [18F] FLT uptake and histologic Ki-67 distribution in preliminary studies. Conclusions: FLT-PET is suitable and more specific than FDG-PET for depicting early reductions in tumor proliferation that precede tumor size changes after chemoradiotherapy.
UR - http://www.scopus.com/inward/record.url?scp=33748049814&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748049814&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-05-2720
DO - 10.1158/1078-0432.CCR-05-2720
M3 - Article
C2 - 16899606
AN - SCOPUS:33748049814
SN - 1078-0432
VL - 12
SP - 4590
EP - 4597
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 15
ER -